Central Laboratories White Papers & Articles

  1. AI Tools In Informed Consent: What Sponsors Need To Know About Risk 8/1/2026

    AI tools carry different risks. See how they can impact participant communications, where bias and inaccuracies emerge, and why human review is critical to protecting study integrity.

  2. From Data Delays To Decision Speed 7/31/2026

    The biggest risk in modern trials isn’t missing data. It’s delayed insight. Discover how real-time intelligence helps teams act faster, reduce risk, and improve trial execution.

  3. Why Legacy RTSM Systems Create Risk in Biosimilar Trials 7/31/2026

    Learn how real-time visibility, adaptive supply planning, and proactive risk management can reduce waste and improve study execution.

  4. The FDA Just Rewrote The Rules For Clinical Trials. Here's What It Means For RTSM. 7/30/2026

    Learn how evolving trial designs are changing RTSM requirements and driving demand for greater flexibility, traceability, and execution quality.

  5. The Agentic AI Readiness Myths Costing Sponsors Time 7/30/2026

    Many clinical organizations believe they must clean data and unify systems before adopting agentic AI. New approaches show teams can start now, create value faster, and improve readiness as they scale.

  6. Why Trial Expertise Makes Or Breaks Clinical AI 7/30/2026

    What makes AI effective in clinical trials? See how a top 5 pharma sponsor achieved a 62% reduction in CRA task time and 99% document classification accuracy by prioritizing clinical fluency.

  7. Real-Time Trials Need Real-Time Data You Can Trust 7/30/2026

    The FDA just kicked off real-time clinical trials with AstraZeneca and Amgen. But speed means nothing if the underlying data is inconsistent.

  8. Agentic AI Is Reshaping Clinical Monitoring And The CRA Role Again 7/30/2026

    See why this isn't about replacing CRAs, but freeing them from the admin grind so they can focus on judgment, site relationships, and the work that actually moves trials forward.

  9. What Controlled Immune Challenges Reveal Before Patient Studies Begin 7/30/2026

    Controlled immune challenges can reveal target engagement and pharmacology before efficacy is measurable, supporting earlier and more informed development decisions.

  10. Subject Matter Experts Matter In Decision-Making 7/21/2026

    Expert-led ontology and taxonomy practices help organize data into meaningful hierarchies, making it easier to connect diseases, drug targets, and strategic insights that support stronger decisions.